Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on ...

The addition of nab-paclitaxel to gemcitabine and cisplatin did not improve survival in advanced biliary tract cancer.

Bile duct disorders can lead to serious complications if left untreated, but early diagnosis and proper management can prevent long-term damage, a doctor states. READ ON to find out more.

Delcath Systems, Inc. ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced an update to the ...

The lab of Dr. Mark Magnuson, Louise B. McGavock Professor and professor of molecular physiology and biophysics at Vanderbilt ...

Alnylam Pharmaceuticals (NASDAQ:ALNY), with a market capitalization of $35.4 billion, has emerged as a leading player in the RNA interference (RNAi) therapeutics space, with a particular focus on ...

New research shows potent in vivo gene editing in skeletal muscle of non-human primates by a novel, ultracompact CRISPR system delivered via a single AAV vector This study describes the discovery ...

that establishes proof-of-concept of NanoCas™, the first ultracompact CRISPR system capable of efficient extrahepatic editing when delivered systemically using a single adeno-associated viral (AAV) ...

“We have been focused on discovering and engineering novel ultracompact CRISPR systems at Mammoth and are excited to share the first demonstration of robust in vivo extrahepatic editing in a muscle ...

Although much research on the mechanisms of portal hypertension has focused on liver fibrosis, less attention has been given to the role of intrahepatic and extrahepatic vascular dysfunction, ...